


IN THE CLAIMS:

Please amend claim 1 as follows:

1. (Currently amended) Method of using therapeutically effective amounts of compounds of formula (I):

$(T)_x A-B-D-E-CO_2H$ wherein $(T)_x A$ is



and

each T represents a substituent group, independently selected from the group consisting of:

- the halogens -F, -Cl, -Br, and -I;
- alkyl of 1 - 10 carbons;
- haloalkyl of 1 - 10 carbons;
- haloalkoxy of 1 - 10 carbons;
- alkenyl of 2 - 10 carbons;
- alkynyl of 2 - 10 carbons;
- $-(CH_2)_p Q$, wherein

Amendments to the Claims

Page 1 of 15

p is 0 or an integer 1 - 4,

- -alkenyl-Q, wherein

said alkenyl moiety consists of 2 - 4 carbons, and

- alkynyl-Q, wherein

said alkynyl moiety consists of 2 - 7 carbons; and

Q is selected from the group consisting of aryl of 6 - 10 carbons, heteroaryl consisting of 4 - 9 carbons and at least one N, O, or S

heteroatom, -CN, -CHO, -NO₂, -CO₂R², -OCOR², -SOR³, -SO₂R³, -CON(R⁴)₂, -SO₂N(R⁴)₂, -C(O)R², -N(R⁴)₂, -N(R²)COR², -N(R²)CO₂R³, -N(R²)CON(R⁴)₂, -CHN₄, -OR⁴, and -SR⁴;

wherein

R² represents H;

alkyl of 1 - 6 carbons;

aryl of 6 - 10 carbons;

heteroaryl consisting of 4 - 9 carbons and at least one N, O, or S

heteroatom; or

arylalkyl in which the aryl portion contains 6-10 carbons and the alkyl portion consists of 1 - 4 carbons; or

heteroaryl-alkyl in which the heteroaryl portion consists of 4-9 carbons and at least one N, O, or S heteroatom and the alkyl portion consists of 1-4 carbons;

Amendments to the Claims

Page 2 of 15

R^3 represents alkyl of 1-4 carbons;

aryl of 6-10 carbons;

heteroaryl consisting of 4 - 9 carbons and at least one N, O, or S

heteroatom; or

arylalkyl in which the aryl portion consists of 6 - 10 carbons and the alkyl portion consists of 1 - 4 carbons; or

heteroaryl-alkyl in which the heteroaryl portion consists of 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion consists of 1 - 4 carbons;

R^4 represents H;

alkyl of 1 - 12 carbons;

aryl of 6 - 10 carbons;

heteroaryl consisting of 4 - 9 carbons and at least one N, O, or S








heteroatom;

arylalkyl in which the aryl portion consists of 6 - 10 carbons and the alkyl portion consists of 1 - 4 carbons;

heteroaryl-alkyl in which the heteroaryl portion consists of 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion consists of 1-4 carbons;


alkenyl of 2 - 12 carbons;

alkynyl of 2 - 12 carbons;



wherein R^1 is as defined above and each R^1 may be the same or different:

(c) D represents



Amendments to the Claims

Page 5 of 12

d) E represents a chain of n carbon atoms bearing m R^6 groups, wherein said R^6 groups are independent, or constitute spiro or nonspiro rings in which

- (a) two groups R^6 are joined, and taken together with the chain atom(s) to which said two R^6 group(s) are attached, and any intervening chain atoms, constitute a 3 - 7 membered ring, or
- (b) one group R^6 is joined to the chain on which said one group R^6 resides, and taken together with the chain atom(s) to which said R^6 group is attached, and any intervening chain atoms, constitutes a 3 - 7 membered ring; and wherein

n is 2 or 3;


m is an integer of 1 - 3;

each group R^6 is independently selected from the group consisting of:

- fluorine;
- hydroxyl, with the proviso that a single carbon may bear no more than one hydroxyl substituent
- alkyl of 1 - 10 carbons;
- aryl of 6 - 10 carbons;
- heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;


- arylalkyl wherein the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 8 carbons;
- heteroaryl-alkyl wherein the heteroaryl portion consists of 4 - 9 carbons and at least one N, O, or S heteroatom, and the alkyl portion consists of 1 - 8 carbons;
- alkenyl of 2 - 10 carbons;
- aryl-alkenyl wherein the aryl portion consists of 6 - 10 carbons and the alkenyl portion consists of 2 - 5 carbons;
- heteroaryl-alkenyl wherein the heteroaryl portion consists of 4 - 9 carbons and at least one N, O, or S heteroatom and the alkenyl portion consists of 2 - 5 carbons;
- alkynyl of 2 - 10 carbons;
- aryl-alkynyl wherein the aryl portion contains 6 - 10 carbons and the alkynyl portion consists of 2 - 5 carbons;
- heteroaryl-alkynyl wherein the heteroaryl portion consists of 4 - 9 carbons and at least one N, O, or S heteroatom and the alkynyl portion contains 2 - 5 carbons;
- $-(CH_2)_tR^7$ wherein t is 0 or an integer of 1 - 5; and

R^7 is selected from the group consisting of



Amendments to the Claims

Page 7 of 15



Amendments to the Claims

and corresponding heteroaryl moieties in which the aryl portion of an arylcontaining R^7 group comprises 4 - 9 carbons and at least one N, O or S heteroatom;

wherein


Y represents O or S;

R^1 , R^2 , and R^3 are as defined above and each R^1 , R^2 or R^3 may be the same or different; and

• $-(CH_2)_vZR^8$ wherein

v is 0 or an integer of 1 to 4;

and Z represents



R^8 is selected from the group consisting of: alkyl

of 1 to 12 carbons;

aryl of 6 to 10 carbons;

heteroaryl consisting of 4 - 9 carbons and at least one N, O, or S heteroatom;

arylalkyl wherein the aryl portion consists of 6 to 10 carbons and the alkyl

Amendments to the Claims

Page 9 of 15

portion ~~contains~~ of 1 to 4 carbons;

heteroaryl-alkyl wherein the aryl portion consists of 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion consists of 1 - 4 carbons;

$-C(O)R^9$ wherein R^9 represents alkyl of 2 - 6 carbons, aryl of 6 - 10 carbons, heteroaryl of 4 - 9 carbons and at least one N, O, or S heteroatom, or arylalkyl in which the aryl portion consists of 6 - 10 carbons or is heteroaryl consisting of 4-9 carbons and at least one N, O, or S heteroatom, and the alkyl portion consists of 1 - 4 carbons;

and with the provisos that when

R^8 is $-C(O)R^9$, Z is S or O;

- when Z is O, R^8 may also be $-(C_qH_{2q}O)_rR^5$ wherein q, r, and R^5 are as defined above; and

- $-(CH_2)_wSiR^3$ wherein

w is an integer of 1 to 3; and

R^{10} represents alkyl of 1 to 2 carbons;

and with the proviso that

- aryl or heteroaryl portions of any of said T or R^6 groups optionally may

Amendments to the Claims

Page 10 of 15


bear up to two substituents selected from the group consisting of
 $-(CH_2)_yC(R^4)(R^3)OH$, $-(CH_2)_yOR^4$, $-(CH_2)_ySR^4$, $-(CH_2)_yS(O)_2R^4$,
 $-(CH_2)_yS(O)_2R^4$, $-(CH_2)_ySO_2N(R^4)_2$, $-(CH_2)_yN(R^4)_2$,
 $-(CH_2)_yN(R^4)COR^3$, $-OC(R^4)_2O-$ in which both oxygen atoms are connected to the
 aryl ring, $-(CH_2)_yCOR^4$, $-(CH_2)_yCON(R^4)_2$,
 $-(CH_2)_yCO_2R^4$, $-(CH_2)_yOCOR^4$, -halogen, -CHO, -CF₃, -NO₂, -CN, and
 $-R^3$, wherein

y is 0 - 4; and

R^3 and R^4 are defined as above, and each R^3 or R^4 may be the same or
 different; and any two R^4 which are attached to one nitrogen may be joined
 to form a heterocycle;

and wherein at least one pharmaceutically acceptable salt compound is
 administered for the treatment and prevention of cerebral disease.


2. (Currently amended) Method according to claim 1, wherein R^6 is $-(CH_2)_tR^7$, in which t is 0 or
 an integer 1-5, and R^7 is a group of the formula



and wherein at least one pharmaceutically acceptable salt compound is
 administered for the treatment and prevention of cerebral disease.

Amendments to the Claims


3. (Currently amended) Method according to claim 1, where E represents a chain of 2 carbon atoms bearing 1 substituent R^6 , and wherein R^6 is $-(CH_2)_tR^7$, in which $t=0$ or an integer 1-5, and R^7 is a group of the formula



and wherein at least one pharmaceutically acceptable salt compound is administered for the treatment and prevention of cerebral disease.

4. (Currently amended) Method according to claim 1, wherein

(a) $(T)_xA$ represents a group of the formula



Amendments to the Claims

Page 12 of 15


wherein

T represents a substituent group independently selected from the group consisting of


- the halogens -F, -Cl, -Br, and -I;
- alkyl of 1 - 10 carbons; and
- $-(CH_2)_pQ$, wherein p is 0 or an integer 1 - 4, and Q is $-OR^4$, wherein R^4 represents alkyl of 1-12 carbons;

and x = 0, 1 or 2;

(b) B represents a group of the formula



(c) D represents




(d) E represents a group of the formula $-CH_2-CHR^6-$, wherein

R^6 is a group of the formula $-(CH_2)_tR^7$,

wherein t is 0 or an integer of 1 - 5; and

R^7 is a group of the formula



with the proviso that the aryl portion of said R^6 group optionally may bear up to two substituents selected from the group consisting of -halogen, -CHO, $-CF_3$, $-NO_2$, and -CN,

and wherein at least one pharmaceutically acceptable salt compound is administered for the treatment and prevention of cerebral disease.

5. (Original) Method according to claim 2, wherein the compound of the general formula (I) is an alkali metal salt or an alkaline earth metal salt.

6. (Original) Method according to claim 2, wherein the compound of the general formula (I) is a sodium salt.

7. (Original) Method according to claim 2, wherein the application is parenteral.

8. (Original) Method according to claim 2, wherein the application is intravenous.

9. (Original) Alkali metal salt or alkaline earth metal salt of a compound of the general formula (1) according to claim 2

10. (Original) 4-(4'-Chloro-biphenyl-4-yl)-4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)ethyl)-butyric acid sodium.

11. (Canceled).

12. A pharmaceutical composition comprising at least one compound according to claim 9 and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising at least one compound according to claim 10 and a pharmaceutically acceptable carrier.